Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Vor Biopharma, retaining the price target of $31.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Swayampakula Ramakanth has given his Buy rating due to a combination of factors, including the strong clinical validation of telitacicept and Vor Biopharma’s strategic positioning. The interim Phase 3 TELIGAN results published in the New England Journal of Medicine show meaningful reductions in proteinuria, preservation of kidney function, and a favorable safety profile, reinforcing confidence in telitacicept’s efficacy and risk-benefit balance.
Ramakanth also highlights the significant growth runway driven by indication expansion and global development plans. Vor holds exclusive ex-China rights and is advancing two Phase 3 UPSTREAM programs in generalized myasthenia gravis and Sjögren’s disease, targeting an initial U.S. patient pool of roughly 380,000 that could exceed 1 million with broader autoimmune use, while real-world use in China supports commercial viability; accordingly, he reiterates a Buy rating with an unchanged $31 price target.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VOR in relation to earlier this year.